Characterizing Long COVID: Deep Phenotype of a Complex Condition.

COVID-19 human phenotype ontology long COVID of post-acute sequelae of SARS-CoV-2 phenotyping

Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 10 09 2021
revised: 22 10 2021
accepted: 15 11 2021
pubmed: 29 11 2021
medline: 6 1 2022
entrez: 28 11 2021
Statut: ppublish

Résumé

Numerous publications describe the clinical manifestations of post-acute sequelae of SARS-CoV-2 (PASC or "long COVID"), but they are difficult to integrate because of heterogeneous methods and the lack of a standard for denoting the many phenotypic manifestations. Patient-led studies are of particular importance for understanding the natural history of COVID-19, but integration is hampered because they often use different terms to describe the same symptom or condition. This significant disparity in patient versus clinical characterization motivated the proposed ontological approach to specifying manifestations, which will improve capture and integration of future long COVID studies. The Human Phenotype Ontology (HPO) is a widely used standard for exchange and analysis of phenotypic abnormalities in human disease but has not yet been applied to the analysis of COVID-19. We identified 303 articles published before April 29, 2021, curated 59 relevant manuscripts that described clinical manifestations in 81 cohorts three weeks or more following acute COVID-19, and mapped 287 unique clinical findings to HPO terms. We present layperson synonyms and definitions that can be used to link patient self-report questionnaires to standard medical terminology. Long COVID clinical manifestations are not assessed consistently across studies, and most manifestations have been reported with a wide range of synonyms by different authors. Across at least 10 cohorts, authors reported 31 unique clinical features corresponding to HPO terms; the most commonly reported feature was Fatigue (median 45.1%) and the least commonly reported was Nausea (median 3.9%), but the reported percentages varied widely between studies. Translating long COVID manifestations into computable HPO terms will improve analysis, data capture, and classification of long COVID patients. If researchers, clinicians, and patients share a common language, then studies can be compared/pooled more effectively. Furthermore, mapping lay terminology to HPO will help patients assist clinicians and researchers in creating phenotypic characterizations that are computationally accessible, thereby improving the stratification, diagnosis, and treatment of long COVID. U24TR002306; UL1TR001439; P30AG024832; GBMF4552; R01HG010067; UL1TR002535; K23HL128909; UL1TR002389; K99GM145411.

Sections du résumé

BACKGROUND BACKGROUND
Numerous publications describe the clinical manifestations of post-acute sequelae of SARS-CoV-2 (PASC or "long COVID"), but they are difficult to integrate because of heterogeneous methods and the lack of a standard for denoting the many phenotypic manifestations. Patient-led studies are of particular importance for understanding the natural history of COVID-19, but integration is hampered because they often use different terms to describe the same symptom or condition. This significant disparity in patient versus clinical characterization motivated the proposed ontological approach to specifying manifestations, which will improve capture and integration of future long COVID studies.
METHODS METHODS
The Human Phenotype Ontology (HPO) is a widely used standard for exchange and analysis of phenotypic abnormalities in human disease but has not yet been applied to the analysis of COVID-19.
FUNDING BACKGROUND
We identified 303 articles published before April 29, 2021, curated 59 relevant manuscripts that described clinical manifestations in 81 cohorts three weeks or more following acute COVID-19, and mapped 287 unique clinical findings to HPO terms. We present layperson synonyms and definitions that can be used to link patient self-report questionnaires to standard medical terminology. Long COVID clinical manifestations are not assessed consistently across studies, and most manifestations have been reported with a wide range of synonyms by different authors. Across at least 10 cohorts, authors reported 31 unique clinical features corresponding to HPO terms; the most commonly reported feature was Fatigue (median 45.1%) and the least commonly reported was Nausea (median 3.9%), but the reported percentages varied widely between studies.
INTERPRETATION CONCLUSIONS
Translating long COVID manifestations into computable HPO terms will improve analysis, data capture, and classification of long COVID patients. If researchers, clinicians, and patients share a common language, then studies can be compared/pooled more effectively. Furthermore, mapping lay terminology to HPO will help patients assist clinicians and researchers in creating phenotypic characterizations that are computationally accessible, thereby improving the stratification, diagnosis, and treatment of long COVID.
FUNDING BACKGROUND
U24TR002306; UL1TR001439; P30AG024832; GBMF4552; R01HG010067; UL1TR002535; K23HL128909; UL1TR002389; K99GM145411.

Identifiants

pubmed: 34839263
pii: S2352-3964(21)00516-8
doi: 10.1016/j.ebiom.2021.103722
pmc: PMC8613500
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103722

Subventions

Organisme : NIDDK NIH HHS
ID : K23 DK124654
Pays : United States
Organisme : NCATS NIH HHS
ID : U24 TR002306
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002389
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG010067
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL128909
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002535
Pays : United States
Organisme : NIGMS NIH HHS
ID : K99 GM145411
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG024832
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001439
Pays : United States

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest RRD, TDB, JBB, CGC, WBH, JAM, AMP, ERP, HMR, JS, RAS, AES, JS, GS, MAH, PNR report funding from NIH. MAH and JAM are co-founders of Pryzm Health.

Auteurs

Rachel R Deer (RR)

University of Texas Medical Branch, Galveston, TX, USA. Electronic address: rrdeer@utmb.edu.

Madeline A Rock (MA)

University of Texas Medical Branch, Galveston, TX, USA.

Nicole Vasilevsky (N)

Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Monarch Initiative.

Leigh Carmody (L)

Monarch Initiative; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

Halie Rando (H)

Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Alfred J Anzalone (AJ)

Department of Neurological Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Marc D Basson (MD)

Department of Surgery, University of North Dakota School of Medicine and Health Sciences.

Tellen D Bennett (TD)

Section of Informatics and Data Science, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Timothy Bergquist (T)

Sage Bionetworks, Seattle, WA.

Eilis A Boudreau (EA)

Department of Neurology; Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, OR 97239.

Carolyn T Bramante (CT)

Departments of Internal Medicine and Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455.

James Brian Byrd (JB)

Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, 48109.

Tiffany J Callahan (TJ)

Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Lauren E Chan (LE)

Monarch Initiative; College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.

Haitao Chu (H)

Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN USA.

Christopher G Chute (CG)

Johns Hopkins University, Schools of Medicine, Public Health, and Nursing, Baltimore, MD, USA.

Ben D Coleman (BD)

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Institute for Systems Genomics, University of Connecticut, Farmington, CT 06032, USA.

Hannah E Davis (HE)

Patient-Led Research Collaborative.

Joel Gagnier (J)

Departments of Orthopaedic Surgery & Epidemiology, University of Michigan, Ann Arbor, MI, USA.

Casey S Greene (CS)

Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

William B Hillegass (WB)

University of Mississippi Medical Center, University of Mississippi Medical Center, Jackson, MS, USA; Departments of Data Science and Medicine.

Ramakanth Kavuluru (R)

Institute for Biomedical Informatics, University of Kentucky.

Wesley D Kimble (WD)

West Virginia Clinical and Translational Science Institute, West Virginia University, Morgantown, WV, USA.

Farrukh M Koraishy (FM)

Division of Nephrology, Department of Medicine, Stony Brook University.

Sebastian Köhler (S)

Monarch Initiative; Ada Health GmbH, Berlin, Germany.

Chen Liang (C)

Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.

Feifan Liu (F)

Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA.

Hongfang Liu (H)

Department of Artificial Intelligence and Informatics, Mayo Clinic, MN, USA.

Vithal Madhira (V)

Palila Software LLC, Reno, NV, USA.

Charisse R Madlock-Brown (CR)

Department of Diagnostic and Health Sciences, University of Tennessee Health Science Center, 920 Madison Ave. Suite 518N, Memphis TN 38613.

Nicolas Matentzoglu (N)

Monarch Initiative; Semanticly Ltd; European Bioinformatics Institute (EMBL-EBI).

Diego R Mazzotti (DR)

Division of Medical Informatics, Department of Internal Medicine, University of Kansas Medical Center.

Julie A McMurry (JA)

Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Monarch Initiative.

Douglas S McNair (DS)

Quantitative Sciences, Global Health Div., Gates Foundation, Seattle, WA 98109, USA.

Richard A Moffitt (RA)

Stony Brook University, Stony Brook, NY 11794, USA.

Teshamae S Monteith (TS)

University of Miami, Miller School of Medicine, Miami, Fl 33136.

Ann M Parker (AM)

Pulmonary and Critical Care Medicine, Johns Hopkins University, Schools of Medicine, Baltimore, MD, USA.

Mallory A Perry (MA)

Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, USA.

Emily Pfaff (E)

University of North Carolina, Chapel Hill.

Justin T Reese (JT)

Monarch Initiative; Lawrence Berkeley National Laboratory.

Joel Saltz (J)

Stony Brook University; Biomedical Informatics.

Robert A Schuff (RA)

OCHIN, Inc Portland, OR, USA.

Anthony E Solomonides (AE)

Outcomes Research Network, Research Institute, NorthShore University HealthSystem, Evanston, IL 60201, USA; Institute for Translational Medicine, University of Chicago, Chicago, IL, USA.

Julian Solway (J)

Institute for Translational Medicine, University of Chicago, Chicago, IL, USA.

Heidi Spratt (H)

University of Texas Medical Branch, Galveston, TX, USA.

Gary S Stein (GS)

University of Vermont Larner College of Medicine, Departments of Biochemistry and Surgery, Burlington, Vermont 05405.

Anupam A Sule (AA)

St Joseph Mercy Oakland, Pontiac, MI, USA.

Umit Topaloglu (U)

Wake Forest School of Medicine.

George D Vavougios (GD)

Department of Computer Science and Telecommunications, University of Thessaly, Papasiopoulou 2 - 4, P.C.; 131 - Galaneika, Lamia, Greece; Department of Neurology, Athens Naval Hospital 70 Deinokratous Street, P.C. 115 21 Athens, Greece; Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Biopolis, P.C. 41500 Larissa, Greece.

Liwei Wang (L)

Department of Artificial Intelligence and Informatics, Mayo Clinic, MN, USA.

Melissa A Haendel (MA)

Center for Health AI, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Monarch Initiative. Electronic address: melissa@tislab.org.

Peter N Robinson (PN)

Monarch Initiative; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Institute for Systems Genomics, University of Connecticut, Farmington, CT 06032, USA. Electronic address: peter.robinson@jax.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH